Overall, these data suggest that increased BRD4 activity results in enhanced malignancy only in IDHmut glioma, particularly astrocytomas, whereas increased BRD3 activity results in enhanced survival only in IDHwt glioma. This evidence concerns the gene BRD3 and central nervous system cancer.